Anything above $9 a share is a good short. Anything below $7 is a good buy.
Still doesn't have FDA approval. May get a CRL. Also, still have to ramp revenue vs. entrenched shot competitors who will claim the shot is safer than the inhaler... Net net little risk to short once the stock reaches $9 a share as the stock has little upside left and lots of downside risks.
He's right, Look at all the recent ADCOM or FDA approvals. You might as well be prepared for it now. I'm long this stock, it's not going to stay at 9 for very long. If I was going to short this i would take his advice. You can call him all the names you want but you already seem to have forgot they pushed it down to 3.80 what makes you think they can't push it down again.